



SHUKRA

PHARMACEUTICALS LTD.

8th November, 2023

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai

Scrip Code: 524632

Sub: Outcome of the meeting of the Board of Directors held on Wednesday, November 8, 2023.
Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015.

Dear Sir/Madam,

With reference to above subject and in compliance with Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e., Wednesday, November 8, 2023 at 04:00 p.m. and concluded on 04:45 p.m. *inter alia* considered and approved the following:

1. Un-Audited Financial Results (UFR) for the second quarter and half year ended September 30, 2023, along with the Statutory Auditors' Limited Review Report.
2. Reviewed the other Business of the Company.

You are requested to kindly take the same on record.

Thanking you,


Yours faithfully

For Shukra Pharmaceuticals Limited

Digitally signed by Bhoomiben Nilesbhai Patel
DN: c=IN, o=Personal, title=068,
2.5.4.20=f6ac54828ba44671eb5054ac314d170de6dual36c
5309a34818b5c88c50296, postalCode=382470, st=Gujarat,
serialNumber=9C781ac6060808ba4c1400119a0eul3bcafeaf
fb79abf23b2069f4148724e, cn=Bhoomiben Nilesbhai Patel

Bhoomi Patel
Director
DIN: 08316893

Encl. As Above



CIN : L24231GJ1993PLC019079

SHUKRA PHARMACEUTICALS LIMITED							
CIN: L24231GJ1993PLC019079							
3rd Floor, Dev House, Opposite WIAA Institute, Judges Bunglow Road, Bodakdev, Ahmedabad - 380003							
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HAIF YEAR ENDED 30TH September, 2023							
(Rs. In Lakhs Except EPS)							
Sr. No.	Particulars	30.09.2023 (Unaudited)	QUARTER ENDED 30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	Half Yearly 30-09-2023 (Unaudited)	30-09-2022 (Unaudited)	Year Ended 31.03.2023 (Audited)
1	Income from Operations						
I	Revenue from Operations	2,463.83	2,016.01	372.06	4,479.84	1,028.63	5,883.37
	(a) Net Sales/ Income from Operations	2,463.83	2,016.01	372.06	4,479.84	1,028.63	5,883.37
II	Other Income	24.25	63.36	2.85	87.61	3.66	119.67
	Total Income from Operations (I+II)	2,488.08	2,079.37	374.91	4,567.45	1,032.29	6,003.04
2	Expenses						
	(a) Cost of materials consumed	479.63	202.63	237.51	682.26	605.55	1,135.02
	(b) Purchase of Stock-in Trade	1,093.94	1,603.97	-	2,697.91	-	3,430.02
	(c) Changes in inventories of finished goods, and work-in-progress and stock	194.20	(15.58)	(87.84)	178.62	(54.89)	(33.38)
	(d) Employee Benefit Expenses	137.10	134.45	116.67	271.55	250.40	488.92
	(e) Finance Cost	6.49	8.46	4.32	14.95	15.87	28.08
	(f) Depreciation & Amortisation Expenses	56.17	45.94	45.13	102.11	87.28	183.75
	(g) Other Expenses	50.17	56.83	58.45	107.01	84.89	326.46
	Total Expenses	2,017.70	2,036.70	374.24	4,054.41	989.11	5,558.87
3	Profit / (Loss) before Exceptional and Extra ordinary Items and Tax (1-2)	470.38	42.67	0.67	513.04	43.18	444.17
4	Exceptional Items						-
5	Profit / (Loss) before Extra ordinary items and Tax (3-4)	470.38	42.67	0.67	513.04	43.18	444.17
6	Extra ordinary items						-
7	Net Profit / (Loss) from Ordinary Activities before Tax(5-6)	470.38	42.67	0.67	513.04	43.18	444.17
8	Tax Expenses						
	I. Current Tax	-	-	(9.04)	-	-	-
	II. Deferred Tax	(0.78)	0.64	1.28	(0.14)	1.95	2.72
	II. Tax of Earlier Year	0.23	-	0.80	0.23	0.80	0.80
	IV. MAT Credit Entitlement		-	-			-
9	Net Profit / (Loss) for the Period (7-8)	470.93	42.03	7.64	512.95	40.43	440.65
10	Other Comprehensive Income						(0.94)
	Remeasurement of defined benefit plans	-	-	-	-	-	-
	Prior Period Adjustments & Expenses	-	-	-	-	-	-
11	Total Comprehensive Income for the period (9+10)	470.93	42.03	7.64	512.95	40.43	439.71
12	Paid up Equity Share Capital (F. V. of Re. 1/- Each)	1,086.45	716.25	156.57	1,086.45	156.57	391.42
13	Other Equity excluding Revaluation Reserve	10.00	10.00	10.00	10.00	10.00	10.00
14	Earnings per Share (of Re. 1/- each) :						
	(a) Basic-Rs	1.47	0.59	0.49	2.93	2.58	26.21
	(b) Diluted-Rs	1.47	0.59	0.49	2.93	2.58	26.21

NOTES:

- The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 08th November, 2023. The statutory auditors have carried out review of the results for the quarter ended September 30, 2023.
- The Unaudited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015.
- The Unaudited Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- The figures for the previous period/year have been regrouped / reclassified, wherever necessary.
- During the quarter ended 30th September, 2023, 2 complaints was received and 2 complaint for last quarter attended and closed.
- The Company is operating in single segment, so above results are for single segment only.
- The search Operation was conducted on the business premises of assessee as on 06th November, 2023. The income tax department has Seized the books of accounts and initiated prosecution but quantum of the liabilities is not yet determined.

For and on behalf of Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

Digitally signed by Bhoomiben Nileshbhai Patel
DN: cn=Bhoomiben Nileshbhai Patel, o=SHUKRA PHARMACEUTICALS LIMITED, ou=SHUKRA PHARMACEUTICALS LIMITED, email=bhoomiben@shukrapharma.com, c=IN
2.5.4.2b6e6a5c4d5b4a4d71e95054ac314d170de6b136c5309
a34818b6c88c50286, postalCode=382470, st=Gujarat,
serialNumber=c9fc781ac6068088a4c11400119adea438c4ed9fb75a
b7f2352069f4148724c, cn=Bhoomiben Nileshbhai Patel

BHOOMIBEN PATEL
Director
DIN:08316893

Date: 08/11/2023
Place: Ahmedabad

SHUKRA PHARMACEUTICALS LIMITED

CIN: L24231GJ1993PLC019079

Unaudited Standalone Balance Sheet as at 30th September, 2023

(Rs. in Lakhs)

Particulars	As at September 30, 2023	As at March 31, 2023
Assets		
Non-current assets		
Property, plant and equipment	2,023.53	2,023.30
Capital work-in-progress	166.17	166.17
	2,189.70	2,189.47
Current assets		
Inventories	33.24	315.67
Financial assets		
(i) Trade receivables	2,826.80	3,018.67
(ii) Cash and cash equivalents	938.61	397.31
(iii) Loans & Advances	276.71	227.77
Income tax assets (net)	34.82	25.97
Other current assets	1,135.04	1,321.78
	5,245.22	5,307.17
Total assets	7,434.92	7,496.64
Equity and liabilities		
Equity		
Equity share capital	1,086.45	391.42
Other equity	3,331.62	2,138.26
Total equity	4,418.07	2,529.68
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	188.81	376.84
Deferred tax liabilities (net)	328.54	328.68
Other non-current liabilities	10.83	10.83
	528.18	716.35
Current liabilities		
Financial liabilities		
(i) Borrowings	41.87	131.31
(ii) Trade payables	554.98	3,425.06
Other current liabilities	1,891.82	694.25
	2,488.67	4,250.62
Total liabilities	3,016.85	4,966.97
Total equity and liabilities	7,434.92	7,496.64

For and on behalf of Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

Digitally signed by Bhoomiben Nilesbbhai Patel
DN: c=IN, o=Personal, title=4068,
2.5.4.20=f6ac5d828ba1f44671eb5054ac314d170de6dba13
6c5319a34818b6c88c50296, postalCode=382470,
st=Gujarat,
serialNumber=c9fc781ac5068088a4c1f400119a6ea438cafe
0ffb79abff23b2069f4148724e, cn=Bhoomiben Nilesbbhai
Patel

Date: 08/11/2023

Place: Ahmedabad

BHOOMIBEN PATEL

Director

DIN:08316893

SHUKRA PHARMACEUTICALS LIMITED

CIN: L24231GJ1993PLC019079

Statement of Unaudited cash Flows for the Half year ended September 30, 2023

Particulars	(Rs. in Lakhs)	
	For the half year ended September 30, 2023	For the half year ended September 30, 2022
Cash flow from operating activities		
Profit before tax as per statement of profit and loss	513.04	43.18
Adjustments for:		
Depreciation and amortisation	102.11	87.28
Sundry Balances Written back	(24.94)	-
Interest expense	14.95	15.87
Interest income	(2.49)	-
Operating profit before working capital changes	602.63	146.33
Movements in working capital :		
(Increase)/decrease in trade receivables	191.87	433.98
(Increase)/decrease in inventories	282.43	115.93
(Increase)/decrease in other assets	134.80	(7.15)
Increase/(decrease) in trade payables	(2,845.13)	(19.47)
Increase/(decrease) in other liabilities	1,108.13	(207.02)
Cash generated from operations	(525.23)	462.60
Direct taxes (paid)/refund (net)	(5.85)	(12.20)
Net cash Inflow / (Outflow) from operating activities (A)	(531.08)	450.40
Cash flows from investing activities		
Purchase of property, plant and equipments (Including capital work in progress, capital advances and capital creditors)	(102.35)	(158.04)
Interest received	2.49	-
(Purchase)/sale of investment	-	(0.31)
Net cash inflow from investing activities (B)	(99.86)	(158.35)
Cash flows from financing activities		
Proceeds/(Repayment) of long-term borrowing	(188.03)	(173.18)
Proceeds from issuance of shares during the year	1,375.22	-
Interest paid	(14.95)	(15.87)
Net cash Inflow from financing activities (C)	1,172.24	(189.05)
Net increase / (decrease) in cash & cash equivalents (A + B + C)	541.30	103.00
Cash and cash equivalents at the beginning of the year	397.31	8.54
Cash and cash equivalents at the end of the period	938.61	111.54
Notes:		
Component of cash and cash equivalents		
Cash on hand	5.87	3.22
On current accounts	932.74	108.33
Cash and Cash Equivalents at the End of the period	938.61	111.54

Note :

(1) The Statement of Cash flows has been prepared under the Indirect method as set out in Ind AS 7 – Statement of Cash flows notified under section 133 of The Companies Act, 2013, read together with paragraph 7 of the Companies (Indian Accounting Standard) Rules 2015 (as amended).

For and on behalf of Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

Digitally signed by Bhoomiben Nileshbhai Patel
DN: c=IN, o=Personal, title=4068,
2.5.4.20=f6ac5d82bba7f44671eb5954ac314d170de6d8a136c53
09a34818b6c8b50296, postalCode=382470, st=Gujarat,
serialNumber=c9cf781ac5968088a4c1f400119a6ea438cafe0ff67
9abff23b2069f4148724e, cn=Bhoomiben Nileshbhai Patel

BHOOMIBEN PATEL
Director
DIN:08316893

Date: 08/11/2023
Place: Ahmedabad

MAAK & ASSOCIATES

Chartered Accountants

Independent Auditor's Limited Review Report on Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company") for the quarter ended September 30, 2023 and year to date from April 01, 2023 to September 30, 2023 (the "Statement") being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended (the 'Listing Regulations').

This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of The Companies Act, 2013, read with relevant Rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter – No such thing requires to be mentioned hence our conclusion is not modified in respect of this matter.

Place: Ahmedabad
Date: 08th November 2023
UDIN: 23133926BGWFGH2342

For MAAK and Associates
Chartered Accountants
FRN: 135024W


Marmik Shah
Partner
M. No. 133926

